Table 1.
Technique (year) | Typea | Basisb | Resolutionc | Detectiond | Amounte | Throughputf | Costg |
---|---|---|---|---|---|---|---|
RAPD (1990) | CNA | Arbitrary primer PCR amplification | Native electrophoresis | Ethidium bromide staining | >10ng | L: ~20–50 S: ~20 |
$1–$2 |
AP-PCR (1990) | CNA | Arbitrary primer PCR amplification | Denaturing electrophoresis | Autoradiography, silver staining or fluorescence | >10ng | L: ~50–100 S: ~40 |
$2–$3 |
CHAPA (2001) | CNA | Arbitrary primer PCR amplification | Microarray slides | Fluorescence | >100ng | L: >1,000 S: 2 |
~$100–$200 |
RLGS-M (1993) | MET | Digestion with NotI or AscI | Bidimensional electrophoresis | Autoradiography | >1μg | L: ~1,000 S: 1 |
~$20 |
MS-AP-PCR (1997) | MET | Arbitrary primer PCR amplification after digestion with HpaII and RsaI | Denaturing electrophoresis | Autoradiography | >100ng* | L: ~50 S: ~40 |
$3–$4 |
MSRF (1997) | MET | Arbitrary primer PCR amplification after digestion with BstUI and MseI | Native electrophoresis | Autoradiography | >100ng* | L: ~50 S: ~40 |
$3–$4 |
AIMS (2002) | MET | Adaptor-mediated PCR amplification after digestion with SmaI and XmaI | Denaturing electrophoresis | Autoradiography | >100ng* | L: ~50–100 S: ~20 |
$3–$5 |
MS-AFLP (2001) | MET | Adaptor-mediated PCR amplification after digestion with NotI and MseI | Denaturing electrophoresis | Autoradiography or fluorescence | >100ng* | L: ~50–100 S: ~20 |
$3–$5 |
Array-MS-AFLP (2004) | MET CNA |
Adaptor-mediated PCR amplification after digestion with NotI and MseI | Microarray slides | Fluorescence | >1μg | L: ~10,000h S: 2 |
~$100–$200 |
OTHER NON-DNA FINGERPRINTING TECHNIQUESi | |||||||
Agilent CGH arrays | CNA | Hybridization of labeled genomic DNA fragments | Microarray slides | Fluorescence | >500ng | L: 104–106 S: 1–8 |
~$200–$500 |
Illumina Goldengate | CNA MET |
Hybridization or single nucleotide extension of labeled DNA fragments | Microarray slides | Fluorescence | 200ng-1μg | L: 104–106 S: 1–12 |
~$200–$500 |
Affimetrix arrays | CNA | Hybridization of labeled genomic DNA fragments | Microarray slides | Fluorescence | >500ng | L: 104–106 S: 1–96 |
~$200–$500 |
CHARM | MET | McrBC-fractionated DNA libraries | Microarray slides | Fluorescence | >3μg | L: 44,000 S: 2 |
~$200 |
CNA: copy number alterations. MET: DNA methylation alterations.
Key feature that underlies the method is listed.
Method for resolving DNA sequences. Except RAPD that may use agarose gel electrophpresis, the rest of the fingerprinting techniques use polyacrylamide or derivatives (i.e., sequagel) gel electrophoresis.
Method of detection of the DNA sequences.
Values indicate amount of genomic DNA for the initial digestions. Amounts of sample loaded in the electrophesis for the fingerprinting techniques (*) are less (5–10ng).
L: loci per sample; S: number of samples per gel. The values given for the fingerprinting techniques
The cost in US dollars per DNA sample is given as an approximation in a wide range (i.e., depending on whether the analysis is by autoradiography or fluorescence). Costs for fingerprinting techniques include the costs of electrophoresis but not the costs of sample DNA preparation. Costs can be calculated per Mb of genome covered by the techniques, by increasing the number of experiments with different primers. For instance, a map by AP-PCR of random genome sites at a 10Mb resolution for copy number alterations that could provide panoramic views of the degree of disruption of the cancer genome would cost around 6 (primers) X $2–3 = ~$15 per sample, and a map by MS-AFLP of NotI sites at ~10Mb resolution for DNA methylation alterations would cost around 6 (primers) X $3–$5 = ~$25. To reach 1Mb resolution would cost 10 times more, without counting the labor. More than 1Mb resolution would be impractical for DNA fingerprinting technologies.
The current limitation is imposed by the number of NotI sites in the genome, not by the technique itself.
The list is not exhaustive, and is only intended to contrast some differences in throughput and cost for comparative purposes. Massive sequencing approaches (i.e., Illumina Solexa Technology, Roche 454 or Applied Biosystems SOLiD) are not included because it is difficult to calculate the cost per sample depending on the extent of the analysis.